EMBC
Embecta Corp.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.29
+1.93%Next report
Analyst consensus
- Next report date
- Nov 24, 2026
- EPS estimate
- $0.31
- Revenue estimate
- $268.4M
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- $0.56
- EPS estimate
- $0.27
- Revenue actual
- $271.7M
- Revenue estimate
- $256.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +12.8%
- Revenue beats (12Q)
- 8
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 7, 2026 | $0.27 | $0.56 | Beat 110.68% | $271.7M |
| May 5, 2026 | $0.43 | $0.27 | Miss -37.06% | $221.8M |
| Feb 5, 2026 | $0.67 | $0.71 | Beat 5.65% | $261.2M |
| Nov 25, 2025 | $0.70 | $0.50 | Miss -28.16% | $264.0M |
| Aug 8, 2025 | $0.46 | $1.12 | Beat 146.15% | $295.5M |
| May 9, 2025 | $0.66 | $0.70 | Beat 6.06% | $259.0M |
| Feb 6, 2025 | $0.45 | $0.65 | Beat 44.12% | $261.9M |
| Nov 26, 2024 | $0.36 | $0.45 | Beat 25.00% | $286.1M |
| Aug 9, 2024 | $0.48 | $0.74 | Beat 54.17% | $272.5M |
| May 9, 2024 | $0.43 | $0.67 | Beat 55.81% | $287.2M |
| Feb 9, 2024 | $0.45 | $0.61 | Beat 35.56% | $277.3M |
| Nov 21, 2023 | $0.42 | $0.59 | Beat 40.48% | $281.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 24, 2026